Field study conducted in Tunisia to evaluate efficacy of an O-BFS vaccine

Similar documents
FMD in Tunisia Update situation Critical review Vaccination programme

FAO Collaborative Study Phase XVII: Standardisation of FMD Antibody Detection

High potency vaccines induce protection against heterologous challenge with FMD virus

Foot and Mouth Disease Middle East situation Summary of Answers to the Questionnaire Beirut, Lebanon, 7 9 April 2009

Toward the control of Foot-and-Mouth disease in East Asia

Development of a predictive model for vaccine matching for serotype O FMDV from serology and capsid sequence

Verification of Efficacy of Donated FMD O Type Vaccines in Laos

A solid-phase competition ELISA for measuring antibody to foot-and-mouth disease virus

Vaccine matching. Reliability of foot-and-mouth disease r-values. determination

FMD Vaccine Strain Selection

External Quality Assurance: Subregional experiences on RVF

Longevity of the antibody response in pigs and sheep following a single administration of high potency emergency FMD vaccines

Manufacturers expected contribution to the progressive control of Foot-and-Mouth Disease in South Asia

16 th JPC REMESA meeting

Appendix 30. Preliminary results to evaluate cross-protection between O 1 Manisa and O 1 Campos in cattle

COMPARISON OF THREE ELISA KITS FOR THE DETECTION OF ANTIBODIES AGAINST FOOT-AND-MOUTH DISEASE VIRUS NON-STRUCTURAL PROTEINS

Longevity of protection in cattle following vaccination with emergency FMD vaccines from the UK strategic reserve

Component 2.3 Support to REMESA

WEST EURASIA FMD LAB PHASE ACTIVITY PROPOSAL. A. Naci BULUT Head of the Diagnosis Department, Şap Institute

Simultaneous immunization of cattle with FMD and live anthrax vaccines

Appendix 72 Using NSP ELISA (Chekit-FMD-3ABC Bommeli-Intervet) as a Tool for FMDV Serosurveillance in Bulgaria Abstract: Introduction

Elements of FMD post-vaccination monitoring programme / Éléments du programme de surveillance post-vaccination contre la fièvre aphteuse

DIFFERENTIATION OF INFECTION FROM VACCINATION BY DETECTION OF ANTIBODIES TO THE NON-STRUCTURAL PROTEIN 3ABC OF FOOT-AND-MOUTH DISEASE VIRUS

The New FMD Containment Zone Proposal and Vaccination. April 4, 2017, Pirenopolis, Brazil

Results of Seromonitoring in FMD Buffer Zone in the CIS Countries

Requirements of the Terrestrial Code for FMD surveillance. Dr David Paton Dr Gideon Brückner

Global FMD Surveillance and Regional Risks for West Eurasia

The Global FMD situation: SEACFMD in the Global Context

Mechanism of FMD spread in East Asia

Cedivac-FMD; Duration of Immunity in cattle, sheep and pigs. 2004, 8203 AA Lelystad, The Netherlands * Corresponding Author

FMD in Libya. Dr. Abdunaser Dayhum National Center of Animal Health Libya

FMD vaccination and postvaccination. guidelines. Samia Metwally (FAO) Animal Production and Health Division FAO of the United Nations Rome, Italy

IgA response of cattle to FMDV infection in probang and saliva samples

Mass vaccination, immunity and coverage: Modelling population protection against FMD in Turkish cattle. Theo Knight-Jones Epidemiologist, ILRI

Foot-and Mouth Disease Ecological Studies In Endemic Settings: Ongoing Studies in Vietnam and Pakistan

Are Dromedary Camels Susceptible or Non-Susceptible to Foot-and-Mouth Disease Serotype O

Lelystad, The Netherlands

OIE RRL-Lanzhou Activities, Research and Lab network

Regional FMD threats to North Africa

Post-Vaccination Monitoring

Validation report. First commercially-available ELISA which allows for the detection of Lumpy Skin Disease antibodies

Global Update EuFMD Exec. Committee

Update from WRLFMD. Donald King

FMD Carrier state and role of carrier buffalo as source of transboundary spread in Southeast Asia and Eastern Asia Satya Parida

FMD regional update Gulf States 2017

Testing the Antibody Response of Pigs to Foot-and- Mouth Disease Vaccines

FMD Control in Dairy Colonies Milk Production System in Pakistan

Exploiting serological data to understand the epidemiology of foot-and-mouth disease virus serotypes circulating in Libya

Open to: Model developers and users with an interest in the objective

FMD - TURKEY. Yener ŞEKERCAN. Veterinary Officer General Directorate of Food and Control Ankara/TURKEY

Republic of Kazakhstan

Syrian Arab Republic. ministry of agriculture and agrarian reform- directorate of animal health- Syria

Vaccine Matching and Development of Appropriate Vaccines

PROGRESS REPORT FOR TURKEY ON FMD SITUATION AND CONTROL MEASURES

COMPARISON OF DIFFERENT ELISA METHODS FOR THE DETECTION OF ANTIBODIES AGAINST FOOT-AND-MOUTH DISEASE VIRUS (FMDV) TYPE O

FMD VACCINE AND VACCINATION. Ahmad Al-Majali Dean, Faculty of Vet Medicine JUST Jordan

Global Update EuFMD Exec. Committee

Findings on FMD in Afghanistan and Pakistan

Strengthening FMD prevention and emergency response capacity in the Trans-Caucasian countries (MTF/INT/003/EEC)

Materials and Methods

Dr Ghazi Yehia OIE Regional Representative for the Middle East

Importance of cell mediated immunity for protection against Foot and Mouth Disease

Direct beneficiary Countries: Georgia, Armenia and Azerbaijan Proposed Implementation date: 1/1/06

Experimental evaluation of foot-and-mouth disease vaccines for emergency use in ruminants and pigs: a review

SEROLOGICAL EVALUATION OF THE IMMUNITY INDUCED IN COMMERCIAL RABBITS BY VACCINATION FOR MYXOMATOSIS AND RHD

THE CYTOPATHOGENIC ACTION OF BLUETONGUE VIRUS ON TISSUE CULTURES AND ITS APPLICATION TO THE DETECTION OF ANTIBODIES IN THE SERUM OF SHEEP.

1. Engineering Foot-and-Mouth Disease Viruses with Improved

Paper on needs and support to be provided to North African countries, members of REMESA regarding the coordinated control of FMD

PPR in Libya. Zakaria Alkhatal. Abdunaser Dayhum and Ibrahim Eldaghayes. Scientific Advisors (NCAH) Libyan CVO, Director General (NCAH)

FMD activities in the North African region since the 2014/2015 epidemic

Key words: foot-and-mouth disease; single emulsion vaccine, saponin, immune response, emergency vaccines.

Appendix 68 3 ABC ELISA for the diagnosis of FMD in Egyptian sheep Abstract Introduction

Regional Status and FMD s Control Strategies in North Africa

The global control of FMD; challenges and opportunities

Engineering Foot-and-Mouth Disease Virus with Improved Properties for the Development of Effective Vaccine Introduction: Materials and methods:

Excretion of bluetongue virus in cattle semen: a feature of laboratory-adapted virus

FMD diagnostics: current developments and application in the context of FMD control in endemic countries Wilna Vosloo

FMD Report - Syria 6 th Regional FMD West Eurasia Roadmap Meeting - Almaty, Kazakhstan 28 to 30 April 2015

Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC

Progressive Control of Foot and Mouth Disease in PAKISTAN

EFSA projects on PPR, sheep pox, lumpy skin disease. Franck Berthe Animal and Plant Health Unit European Food Safety Authority - EFSA

landbouw, natuur en voedselkwaliteit Epidemiological report BTV 6 in the Netherlands

Predicting antigenic sites on the FMDV. F.F. Maree, R. Reeve, B. Blignaut, J.J. Esterhuysen, E. Fry, T. de Beer, E. Rieder and D.

O 38% NVD 42% A 10% Asia 1 9% SAT2 1% SAT1 <1% Institute for Animal Health

Akabane Virus Risk Management in Australia. P.D. Kirkland, EMAI, Camden NSW Australia.

Foot and Mouth Disease Control, A vaccine perspective. John Barlow, DVM PhD

This CRP is proposed for five years with three RCM. To apply, please see our website for directions:

Importance of Vaccines for Managing FMD

Progress on Implementation of Global FMD Control

REGIONAL REFERENCE LABORATORY FOR FMD IN SOUTH EAST ASIA DEPARTMENT OF LIVESTOCK DEVELOPMENT PAKCHONG, NAKHONRATCHASIMA, THAILAND

Regulation of FMD vaccines within the European Union

Foot and Mouth Disease vaccination is effective: Quantification of FMD transmission with and without vaccination

The Global control of FMD - Tools, ideas and ideals Erice, Italy October 2008

INTERNATIONAL WORKSHOP BLUETONGUE VACCINES 19 February 2013, Strasbourg, France ABSTRACTS

Vet. Ital., 40 (4), islands

Situtation of France regarding BTV 8. 8th october 2015 A. Fediaevsky, MAAAF/DGAL/SDSPA/BSA

EPIDEMIOLOGICAL DEVELOPMENTS AND CONTROL OF FOOT AND MOUTH DISEASE IN ASIA

92th Executive committee

Global FMD Surveillance Report

Global Update. EuFMD Exec. Committee. Donald King

Transcription:

Field study conducted in Tunisia to evaluate efficacy of an O-BFS vaccine FAO/OIE Reference Lab for FMD Emiliana Brocchi Institut de la Recherche Vétérinaire de Tunisie - Service Virologie Soufien Sghaier Istituto Zooprofilattico Sperimentale della Lombardia e dell'emilia-romagna Brescia - Italy

Vaccine matching for O/ME-SA/Ind-2001 Performed at WRL Pirbright Field isolate VACCINE STRAIN O-3039 O/TUR/5/09 O Manisa O BFS LIB 1/2013 0,51 >0,84 0,14 LIB 7/2013 >0,85 >0,86 0,16 LIB 17/2013 0,41 0,45 0,14 LIB 22/2013 >0,90 >1,0 0,50 O TUN/01/14 0.27 (VN=182) 0.56 (91) 0.12 (64) 0.15 (72) O ALG/01/14 0.28 (VN=190) 0.49 (82) 0.14 (72) 0.13 (57) NEP 18/2013 NEP 1/2014 SAU 1/2014 UAE 1/2014 UAE 2/2014 Key for results: MATCH (r 1 0.3), NO MATCH (r 1 <0.3), Borderline result (0.28-0.32) In brackets neutralizing titres produced by heterologous vaccine strains 2 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

ObjecBve Predict efficacy of O- BFS vaccine in the Tunisian context METHOD: Evaluate the level of neutralizing anbbodies against the vaccine strain O- BFS and against the FMD circulabng virus in Tunisia (O Tunisia 2014) elicited by one vaccinabon with the O BFS vaccine. Concept: virus neutralizing anbbodies are able to inacbvate virus infecbvity and can be interpreted as esbmate of protecbon. 3 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

Experimental design and criteria Two groups of animals, not exposed to infection, selected for vaccination with O-BFS vaccine Naïve cattle and sheep: non-vaccinated, ideally without maternal antibodies Cattle and sheep previously vaccinated with the Tunisian vaccine (O Manisa + O Tunisa 1999) - five cattle out of 40 and 4 sheeps out of 40 kept as sentinels Sampling scheme Before vaccination (day 0) 5 days post vaccination (5 DPV) : evaluation of early immune-response to vaccine 21 days post-vaccination (21 DPV) : standard time to assess vaccine-induced immune response 4 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

AREAS SELECTED for the vaccination trial OTD MATEUR cattle & sheep prev. vaccinated Beja (cattle) and Medenine (sheep) non-vacc animals

MEDENINE LANDSCAPE SAMPLING

Mateur sheep 7 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

DR. SGHAIER SAMPLING SHEEP in MATEUR 8 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

9 PROF. HAMMAMI VACCINATING SHEEP in MATEUR JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

11 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

Testing scheme Parallel titration of sera by Virus Neutralization Test (VNT) against both: Ø the vaccine strain O-BFS (homologous titres) Ø the Tunisian circulating virus (heterologous titres) In addition to VNT, sera were analysed by ELISA kits for measurement of antibodies to NSP (marker of infection) and to serotype O. 12 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

PREVIOUSLY VACCINATED ANIMALS MEAN VNT TITRES (log2) N. 40 CATTLE (5 sentinels) - N. 40 SHEEP (4 sentinels) Threshold protecbon Threshold protecbon Both cattle and sheep showed low level of antibodies residual from previous vaccination (day 0) The vaccination with O-BFS vaccine elicited a strong and fast (5 DPV) increase of protecting antibodies against both type O strains Homologous titres (O-BFS) are only 2-fold higher than heterologous (field virus) Assuming a VN titre of log 2 6 (1/128) as indicative of protection, the results show that in the vaccinated population a booster vaccination with O-BFS elicits a protective immune-response as soon as 5 DPV 13 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

RESULTS OF INDIVIDUAL ANIMALS (vaccinated cattle) ODT Mateur Cattle (1-10) -------- threshold +/- -------- threshold protection log2 VN titre 0 5 10 15 sentinel sentinel day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV ODT Mateur Cattle (11-20) log2 VN titre 0 5 10 15 sentinel day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV 14 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

RESULTS OF INDIVIDUAL ANIMALS (vaccinated cattle) -------- threshold +/- -------- threshold protection ODT Mateur Cattle (21-30) log2 VN titre 0 5 10 15 sentinel day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV ODT Mateur Cattle ( 31-40) log2 VN titre 0 5 10 15 sentinel day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV 15 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

RESULTS OF INDIVIDUAL ANIMALS (vaccinated sheep) -------- threshold +/- -------- threshold protection ODT Mateur Sheep (1-10) log2 VN titre 0 5 10 15 day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV ODT Mateur Sheep (11-20) log2 VN titre 0 5 10 15 day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV 16 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

RESULTS OF INDIVIDUAL ANIMALS (vaccinated sheep) log2 VN titre 0 5 10 15 sentinel ODT Mateur Sheep (21-30) sentinel -------- threshold +/- -------- threshold protection day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV sentinel ODT Mateur Sheep ( 31-40) sentinel log2 VN titre 0 5 10 15 day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV 17 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

Other assays ELISA for type O antibodies : ü overall the results correlate and confirm those of VNT NSP-Abs (marker of infection): ü all seronegative at day 0 ü sero-conversion (low Ab level) in 5 cattle and 5 sheep at day 21 PV Hypothesis: ü immune-response to residual NSP in vaccine detectable only in few plurivaccinated animals ü circulation of FMD infection at low level few heads infected, no clinical signs (thanks to vaccine immunity) None of the NSP-seropositive animals corresponded to the sentinels, which might have been more susceptible to infection in the case of virus circulation 18 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

NAÏVE ANIMALS NON VACCINATED MEAN VNT TITRES 13 cattle and 21 sheep seronegative for SP and NSP Abs Threshold protecbon Threshold protecbon ü 21 days post-single vaccination cattle and sheep showed a significant sero-conversion ü Heterologous (O Tunisia 14) mean titres were 2-3 fold lower than homologous (O-BFS) ü Antibody levels achieved by this primary immune response were much lower (5-7 fold) than in boosted-vaccinated animals ü Nevertheless, 21 days after a single vaccination, the mean titres towards the field virus overcome the value log 2 7 (1/128), estimated to confer protection. 19 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

RESULTS OF INDIVIDUAL ANIMALS (non vaccinated CATTLE) M Beja Bovine (1-7) -------- threshold +/- -------- threshold protection log2 VN titre 0 5 10 15 day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV M Beja Bovine (8-13) log2 VN titre 0 5 10 15 day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV All cattle showed a sero-conversion, but 2 out of 13 (ie 15% cattle) did not reach a protective immunity against the circulating virus after a single vaccination with O-BFS vaccine 20 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

RESULTS OF INDIVIDUAL ANIMALS (non vaccinated SHEEP) Madeneine Sheep (1-10) -------- threshold +/- -------- threshold protection log2 VN titre 0 5 10 15 day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV Madeneine Sheep (11-20) log2 VN titre 0 5 10 15 day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV 21 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

RESULTS OF INDIVIDUAL ANIMALS (non vaccinated SHEEP) -------- threshold +/- -------- threshold protection Madeneine Sheep (21-29) log2 VN titre 0 5 10 15 day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV day 0 5DPV 21DPV Similarly to cattle: ü all sheep showed sero-conversion at different levels 21 DPV ü all sheep reached protective immunity against the administered vaccine (strain O-BFS) ü but only 70% sheep reached the estimated protective titre against the circulating virus Therefore, one single vaccination with O-BFS is not expected to confer protection to all animals which will be vaccinated for the first time. 22 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

Other assays (non-vaccinated animals) ELISA for type O antibodies ü Overall the results correlate and confirm those of VNT NSP-Abs (marker of infection) ü All animals remained negative for anti-nsp antibodies for the duration of the experiment, proving absence of FMDV circulation 23 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

Direct comparison vaccinated vs naïve PREVIOUSLY VACCINATED SHEEP NAIVE Threshold protecbon Threshold protecbon ü the trend of immune response in the two groups is the same ü focalizing on Abs to the field virus, it is evident that the O-BFS mono-vaccinated sheep reached average titres about 3 log 2, i.e. 8-fold less, than the booster-vaccinated sheep ü 30% of sheep did not achieve a protective immunity against the field Tunisian virus 24 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

Direct comparison vaccinated vs naïve PREVIOUSLY VACCINATED CATTLE NAIVE 14 13 CATTLE - OTD Mateur 14 13 CATTLE - BEJA Mean VN titre (log2) 12 11 10 9 8 7 6 5 4 day 0 5 DPV 21 DPV 12 11 10 9 8 7 6 5 4 day 0 21 DPV Threshold protecbon threshold +/- ü MEAN titre of single-vaccinated animals overcome the estimated protecting level (log 2 = 7, 1/128) also for the field virus, BUT it is about 6-fold less than in the group of booster vaccinated CATTLE ü 15% of cattle did not achieve a protective immunity 25 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

OVERALL CONCLUSIONS The vaccination with O BFS vaccine is expected to induce a good immunity against the O Tunisia 2014 field virus in previously vaccinated animals (thanks to booster effect). However a proportion of naïve animals will not probably achieve a protective immunity with a single vaccination. The results observed at day 0 (before vaccination with O BFS) in the Mateur group (representing the situation of vaccinated farms) reflect the FMD immune status in the Tunisian context during the 2014 outbreak: approximately 50% cattle and 75% sheep showed neutralizing Ab titres against the field circulating virus lower than the estimated threshold of protection, thus indicative of a low protection level in the population. Also distance from last vaccination should be considered among factors that influence population immunity. 26 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi

GENERAL CONCEPTS ü Protective immunity lasts up to 6 months after an initial course of vaccination, depending on the vaccine potency and the antigenic relationship between vaccine and outbreak strains ü An initial course of two vaccinations improves the strength and duration of the antibody response ü Longer lasting protection may develop once animals have received multiple vaccine doses 27 JPC REMESA Heraklion 16 th March 2015 Emiliana Brocchi